Domo, Inc.
NASDAQ:DOMOSoftware - Application
+$0.43 today
- Market cap
- $155.39M
- Beta
- 1.77
- P/E (TTM)
- -1.9
- EPS (TTM)
- -$1.28
Volume 3.18M
Average 1.39M
DOMO Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Domo, Inc.NASDAQ: DOMO
Capital Expenditures · Q1 FY2027 · quarter ended Apr 2026
Capital expenditures declines year over year
Q1 FY2027 capital expenditures of $1.84M (cash outflow) fell 37.1% year over year, behind the -9.9% change in trailing-twelve-month capital expenditures. Sequentially, it fell 22.9% from the prior quarter. Over 3 fiscal years it compounded at +7.6% a year.
Context
- Capital expenditures amounted to 3.1% of revenue in FY2026, up 0.1 pp from a year earlier.
- Capital expenditures grew in size in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -37.1% toward the trailing-twelve-month pace of -9.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2026
- (9.95M) USD
- Year-over-year change
- -5.4%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2026 | 2026-01-31 | (9.95M) | -5.4% |
| FY2025 | 2025-01-31 | (9.45M) | +19.5% |
| FY2024 | 2024-01-31 | (11.73M) | -46.7% |
| FY2023 | 2023-01-31 | (8M) | -22.7% |
| FY2022 | 2022-01-31 | (6.52M) | — |
Capital Expenditures vs competitors
How DOMO compares with its peers on the latest reported figures
- Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -9.9% is the 6th highest of 10, against a peer median of +3.8%.
- Capital expenditures amounts to 2.8% of revenue for DOMO, versus a peer median of 1.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $30.62M USD | +5.0% | +8.0% | 5.4% | |
| LTM Mar 2026 | $13.38M USD | +126.0% | -6.3% | 4.4% | |
| LTM Mar 2026 | $12.67M USD | +41.9% | -10.6% | 1.4% | |
| LTM Mar 2026 | $9.02M USD | +3.8% | -33.5% | 6.0% | |
| LTM Apr 2026 | $8.87M USD | -9.9% | +7.6% | 2.8% | |
| LTM Mar 2026 | $3.85M USD | +19.7% | +31.1% | 0.8% | |
| LTM Mar 2026 | $2.47M USD | -17.8% | -8.6% | 1.0% | |
| LTM Mar 2026 | $243K USD | -85.3% | +16.9% | 0.6% | |
| FY2025 | $33K USD | -99.0% | -88.9% | 6.2% | |
| LTM Mar 2026 | $22K USD | -15.4% | -39.4% | 0.0% | |
NBPNovaBridge Biosciences | LTM Sep 2025 | CN¥41 CNY | — | -94.7% | — |
| Peer median (excluding DOMO) | — | +3.8% | -9.6% | 1.4% | |
Competitors are the stored peer set for DOMO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Jan 2022 | FY2023 Jan 2023 | FY2024 Jan 2024 | FY2025 Jan 2025 | FY2026 Jan 2026 |
|---|---|---|---|---|---|
| Net Income | (102.11M) | (105.55M) | (75.57M) | (81.94M) | (59.34M) |
| Depreciation & Amortization | 10.2M | 10.02M | 24.39M | 26.76M | 9.84M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 0 | 0 | 56.06M |
| Change in Working Capital | 12.31M | (22.93M) | (19.64M) | (25.85M) | (23.52M) |
| Accounts Receivables | (15.88M) | (14.81M) | 11.76M | (4.35M) | (13.91M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 3.76M | 6.95M | (6.97M) | 1.83M | 8.88M |
| Other Working Capital | 24.43M | (15.06M) | (24.43M) | (23.33M) | (18.49M) |
| Other Non-Cash Items | 79.98M | 107.57M | 73.4M | 71.97M | 24.9M |
| Operating Cash Flow | 379K | (10.89M) | 2.58M | (9.05M) | 7.93M |
| Capital Expenditures | (6.52M) | (8M) | (11.73M) | (9.45M) | (9.95M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (6.52M) | (8M) | (11.76M) | (9.45M) | (9.95M) |
| Debt Repayment | 0 | 0 | 0 | 3.3M | (6.79M) |
| Common Stock Issued | 9.75M | 2.42M | 3.47M | 1.91M | 1.33M |
| Common Stock Repurchased | (10.32M) | 0 | 0 | (820K) | (3.25M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | (1M) | 6.5M |
| Financing Cash Flow | (561K) | 2.42M | 3.47M | 3.39M | (2.2M) |
| Effect of Forex Changes | (534K) | (599K) | 145K | (569K) | 1.91M |
| Net Change in Cash | (7.23M) | (17.06M) | (5.56M) | (15.68M) | (2.31M) |
| Free Cash Flow | (6.14M) | (18.89M) | (9.15M) | (18.5M) | (2.02M) |
Domo, Inc.
NASDAQ:DOMO
Intrinsic Alpha fair value
Locked
Current Price
$3.55
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.